Glycopyrronium tosylate

Glycopyrronium tosylate, sold under the brand name Qbrexza in the United States, is a medication used for the treatment of primary axillary hyperhidrosis.^[1][2][3]

Glycopyrronium tosylate

Clinical data
Trade names	Qbrexza, Rapifort
Other names	Glycopyrronium tosilate hydrate (JAN JP)
AHFS/Drugs.com	Monograph
License data	US DailyMed: Glycopyrronium
Routes of administration	Topical
Drug class	Muscarinic antagonist
ATC code	D11AA01 (WHO)
Legal status
Legal status	US: ℞-only[1] In general: ℞ (Prescription only)
Identifiers
CAS Number	1624259-25-1
PubChem CID	121225724
DrugBank	DBSALT002800
ChemSpider	58902513
UNII	1PVF6JLU7B
KEGG	D10939
ChEMBL	ChEMBL3707243
Chemical and physical data
3D model (JSmol)	Interactive image
SMILES O.Cc1ccc(cc1)S(=O)(=O)[O-].C[N+]2(C)CC[C@@H](C2)OC(=O)[C@@](O)(C3CCCC3)c4ccccc4
InChI InChI=1S/C19H28NO3.C7H8O3S.H2O/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;1-6-2-4-7(5-3-6)11(8,9)10;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;2-5H,1H3,(H,8,9,10);1H2/q+1;;/p-1/t17-,19-;;/m0../s1 Key:UOWOLENSDISMPG-FFUVTKDNSA-M

It was approved for medical use in the United States in June 2018,^[4] and in Japan in January 2022.^[5]